We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

Remdesivir and Sarilumab – COVID-19 Clinical Trials Begin

Industry Insight

The Feinstein Institutes is collaborating with Gilead Sciences and Regeneron Pharmaceuticals in an effort to identify effective therapeutic treatments against COVID-19. Technology Networks recently had the pleasure of speaking with Kevin Tracey, CEO and President of the Feinstein Institutes for Medical Research to find out more.

Read more

Cell Signaling Insights Leveraged for Glaucoma and Cancer Therapy Development

Article

In this article, we delve into some of the cell signaling pathways involved in glaucoma and cancer and how they represent promising new approaches to treatment.

Read more

How Scientists Are Confronting Coronavirus: Scripps Research COVID-19 Updates

Video

Around the world, scientists are sharing data, sharing insights, pushing for the best possible vaccines and medications against COVID-19. Virologist Michael Farzan, PhD, describes the scale of the effort underway at Scripps Research.

Watch Now
New Immune Cell on the Block During Viral Lung Infections
News

Scientists have identified a novel group of immune cells in the lungs that are associated with the control of inflammation during viral infections, like influenza or possibly coronavirus. This discovery may help to advance the development of therapeutics to treat inflammation-related lung conditions such as bronchitis, influenza and potentially even COVID-19.

Read more

Molecular Probes for Opioid Receptors
News

Newly developed molecular probes could make it easier to study the behavior of individual opioid receptors in detail.

Read more

COVID-19: Stopgap Measure Proposed for Respiratory Distress
News

Researchers at MIT and the University of Colorado at Denver have proposed a stopgap measure that they believe could help Covid-19 patients who are in acute respiratory distress. By repurposing a drug that is now used to treat blood clots, they believe they could help people in cases where a ventilator is not helping, or if a ventilator is not available.

Read more

Expanding Access to Coronavirus Literature
News

The National Library of Medicine (NLM), part of the National Institutes of Health, is working on multiple fronts to aid in the COVID-19 response through new initiatives with the global publishing community and artificial intelligence researchers.

Read more

"Blink-on-a-chip" Could Test Eye-drop Drugs
News

A new approach could lead to “cornea-on-a-chip” devices that more accurately test the effects of drugs on the human eye.

Read more

$12 M Awarded for New COVID-19 Vaccine Manufacturing Efforts
News

Canadian Prime Minister Justin Trudeau has announced that the University of Saskatchewan's Vaccine and Infectious Disease Organization – International Vaccine Centre VIDO-InterVac will receive $12 million to help address Canada’s shortage of vaccine manufacturing capacity.

Read more

 
 
Advertisement
 

Targeting the Tumor Microenvironment

Article

In this article, we learn why it’s not just the tumor itself that needs to be targeted and hear about research that aims to exploit the tumor microenvironment.

Read more
 
COVID-19 Portal Will Provide Scientists Free Access to Completed Clinical Trial Data
Article

Vivli, the Center for Clinical Research Data, recently issued a press release announcing the launch of the COVID-19 portal, designed to enable the sharing of completed interventional treatment trial data. Technology Networks spoke with Julie Wood, Vivli’s Director of Strategy and Operations, to learn more about the COVID-19 portal and discover how researchers can access the data within the portal.

Read more

Current Efforts in COVID-19 Vaccine Development
Article

In this article, Technology Networks explore the current global efforts underway to develop a vaccine against COVID-19.

Read more

The Future of Pharma Beyond Blockbusters
Article

Each individual’s genetic makeup is slightly different from everyone else’s, so why are we all receiving the same medicine? To put it simply – the lucrative blockbuster business model, which has previously been the key to pharma success, is no longer viable. In a global and fast-moving world, in order to evolve, it’s time to examine new alternatives to the classic structure.

Read more

 
 
 
Advertisement